1374986-68-1

Basic information

• Product Name: N-(5-fluorothiazol-2-yl)-3-(4-((4-methoxypiperidin-1-yl)sulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)benzamide
• Synonyms: N-(5-fluorothiazol-2-yl)-3-(4-((4-methoxypiperidin-1-yl)sulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)benzamide
• CAS NO: 1374986-68-1
• Molecular Weight: 575.682
• Mol File: 1374986-68-1.mol

Chemical Properties

• CAS DataBase Reference: N-(5-fluorothiazol-2-yl)-3-(4-((4-methoxypiperidin-1-yl)sulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-fluorothiazol-2-yl)-3-(4-((4-methoxypiperidin-1-yl)sulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)benzamide(1374986-68-1)
• EPA Substance Registry System: N-(5-fluorothiazol-2-yl)-3-(4-((4-methoxypiperidin-1-yl)sulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)benzamide(1374986-68-1)

Safety Data

• Hazardous Substances Data: 1374986-68-1(Hazardous Substances Data)

Upstream product

• 1393120-28-9 C₂₄H₂₉NO₇S 
• 64588-82-5 5-fluoro-1,3-thiazol-2-amine 
• 4045-24-3 4-methoxypiperidine 

Relevant articles and documents

Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators

A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds.